Transcription factor C/EBPβ isoform ratio regulates osteoclastogenesis through MafB

• Jeske J Smink ^[2] ; Valérie Bégay ^[2] ; Ton Schoenmaker ^[3] ; Esta Sterneck ^[1] ; Teun J de Vries ^[3] ; Achim Leutz ^[2]
  1. [1] National Cancer Institute

     National Cancer Institute

     Estados Unidos

     
  2. [2] Max Delbrueck Center for Molecular Medicine, Berlin, Germany
  3. [3] Departments of Periodontology and Oral Cell Biology, Academic Centre of Dentistry Amsterdam, Universiteit van Amsterdam and Vrije Universiteit, Amsterdam, The Netherlands

  Mostrar afiliaciones +
• Localización: EMBO journal: European Molecular Biology Organization, ISSN 0261-4189, Vol. 28, Nº. 12, 2009, págs. 1769-1781
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Disequilibrium between bone-forming osteoblasts and bone-resorbing osteoclasts is central to many bone diseases. Here, we show that dysregulated expression of translationally controlled isoforms of CCAAT/enhancer-binding protein β (C/EBPβ) differentially affect bone mass. Alternative translation initiation that is controlled by the mammalian target of rapamycin (mTOR) pathway generates long transactivating (LAP*, LAP) and a short repressive (LIP) isoforms from a single C/EBPβ transcript. Rapamycin, an inhibitor of mTOR signalling increases the ratio of LAP over LIP and inhibits osteoclastogenesis in wild type (WT) but not in C/EBPβ null (c/ebpβ−/−) or in LIP knock-in (L/L) osteoclast precursors. C/EBPβ mutant mouse strains exhibit increased bone resorption and attenuated expression of MafB, a negative regulator of osteoclastogenesis. Ectopic expression of LAP and LIP in monocytes differentially affect the MafB promoter activity, MafB gene expression and dramatically affect osteoclastogenesis. These data show that mTOR regulates osteoclast formation by modulating the C/EBPβ isoform ratio, which in turn affects osteoclastogenesis by regulating MafB expression.